Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ACRS with free AI briefings, catalyst countdowns, and dilution alerts.

ACRS · Aclaris Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$204.6M Cash on Hand
27.9mo Cash Runway
8.2% Short Interest
$10.36 Analyst Target (11)
Follow ACRS by email Get an email when ACRS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ACRS, unsubscribe in one click. Privacy

📣 What ACRS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
A-101 Topical Solution Seborrheic Keratosis Phase 4 · NCT03487588 Completed
Active Common Wart Phase 3 · NCT03691831 Completed
Zunsemetinib (ATI-450) Rheumatoid Arthritis Phase 2 · NCT05279417 Completed
ATI-50002 Androgenetic Alopecia Phase 2 · NCT03495817 Completed
ATI-50002 topical solution Vitiligo Phase 2 · NCT03468855 Completed
ATI-501 400mg BID (Low dose) Alopecia Phase 2 · NCT03594227 Completed
ATI-502 Atopic Dermatitis Phase 2 · NCT03585296 Completed
Modzatinib Lichen Planus Phase 2 · NCT07935590 Not yet recruiting
ATI 502 0.46% Topical Solution Alopecia Areata Phase 2 · NCT03759340 Terminated
ATI-045 Atopic Dermatitis Phase 2 · NCT07011706 Active not recruiting
ATI-1777 Atopic Dermatitis Phase 2 · NCT04598269 Completed
ATI-1777 0.5% w/w Atopic Dermatitis Phase 2 · NCT05432596 Completed
ATI-1777 1.0% w/w Atopic Dermatitis Phase 2 · NCT05432596 Completed
ATI-1777 2.0% w/w Atopic Dermatitis Phase 2 · NCT05432596 Completed
ATI-2138 Atopic Dermatitis Phase 2 · NCT06585202 Completed
mFOLFIRINOX Metastatic Pancreatic Ductal Adenocarcinoma Phase 1 · NCT06648434 Recruiting

Also used in these trials (approved or third-party drugs, not ACRS's own candidates): Oxymetazoline Hydrochloride, Capecitabine, Denosumab, Methotrexate, Zoledronic Acid.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ACRS holds $204.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $22M/quarter from operations, an estimated runway of 27.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 29 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ACRS files for a raise →

👥 Who Owns ACRS

Insiders 10.9% Other 5%+ holders 13.8% Institutions (210 holders) 75.3% Public and other holders 0%
HolderTypeShares% of sharesAs of
Braden Michael Leonard
10% owner
Insider 13,950,000 8.80% 2026-04-27
BML Investment Partners, L.P. 5%+ holder (13G) 13,950,000 8.80% 2026-04-23
RA Capital Management, L.P. Institution (13G, 5%+) 12,723,026 8.02% 2026-06-30
BML Capital Management, LLC Institution (13F) 10,955,000 6.91% 2026-09-30
Deep Track Capital, LP Institution (13G, 5%+) 9,345,000 5.89% 2026-03-09
Frazier Life Sciences Public Fund, L.P. 5%+ holder (13G) 7,879,943 4.97% 2026-09-14
FMR, LLC Institution (13F) 7,048,161 4.44% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 6,700,629 4.22% 2025-12-31
Vivo Capital, LLC Institution (13F) 6,694,637 4.22% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 5,864,619 3.70% 2026-09-30
Neal Walker
CEO, Director · +1.15M options
Insider 1,543,886 0.97% 2026-02-03
Anand Mehra
Director · +84,700 options
Insider 726,403 0.46% 2026-06-04

Share count 158,612,149 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-08-01
filed 2026-08-04
Kolbeck Roland Wilhelm
Tax withholding (F) 12,385 $5.20 23,990
2026-08-01
filed 2026-08-04
Kolbeck Roland Wilhelm
Option exercise (M) 36,375 – –
2026-08-01
filed 2026-08-04
Kolbeck Roland Wilhelm
Option exercise (M) 36,375 – 36,375
2026-06-05
filed 2026-06-08
Humphries William D.
Option exercise (M) 11,580 – –
2026-06-05
filed 2026-06-08
SCHIFF ANDREW N
Option exercise (M) 11,580 – 25,540

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full ACRS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ACRS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.